Brain Ischemia - Pipeline Review, H2 2015

Published: Oct, 2015 | Pages: 66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Brain Ischemia - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Brain Ischemia - Pipeline Review, H2 2015', provides an overview of the Brain Ischemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Ischemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Brain Ischemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Brain Ischemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Brain Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Brain Ischemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Brain Ischemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Brain Ischemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents
 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Brain Ischemia Overview 7
Therapeutics Development 8
Pipeline Products for Brain Ischemia - Overview 8
Pipeline Products for Brain Ischemia - Comparative Analysis 9
Brain Ischemia - Therapeutics under Development by Companies 10
Brain Ischemia - Therapeutics under Investigation by Universities/Institutes 11
Brain Ischemia - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Brain Ischemia - Products under Development by Companies 14
Brain Ischemia - Products under Investigation by Universities/Institutes 15
Brain Ischemia - Companies Involved in Therapeutics Development 16
CohBar Inc. 16
Immune Pharmaceuticals Inc. 17
Lixte Biotechnology Holdings, Inc. 18
NeuroNascent, Inc. 19
NeurOp, Inc 20
Prolong Pharmaceuticals 21
Spectrum Pharmaceuticals, Inc. 22
Sylentis S.A. 23
The International Biotechnology Center (IBC) Generium 24
Vect-Horus S.A.S 25
Brain Ischemia - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
AB-002 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
F-573 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
GNR-014 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Humanin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
LAU-0901 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
LB-100 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
LB-102 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NP-10679 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
phycocyanobilin - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Sanguinate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules for Brain Ischemia - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecules to Antagonize Gpr17 for Brain Ischemia - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
SPI-1620 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Stem Cell Therapy for Ischemia - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Synthetic Peptide for Central Nervous System Disorders - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
VHN-439 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Brain Ischemia - Recent Pipeline Updates 60
Brain Ischemia - Dormant Projects 63
Brain Ischemia - Discontinued Products 64
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 65
Disclaimer 66

List of Tables

Number of Products under Development for Brain Ischemia, H2 2015 8
Number of Products under Development for Brain Ischemia - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Brain Ischemia - Pipeline by CohBar Inc., H2 2015 16
Brain Ischemia - Pipeline by Immune Pharmaceuticals Inc., H2 2015 17
Brain Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015 18
Brain Ischemia - Pipeline by NeuroNascent, Inc., H2 2015 19
Brain Ischemia - Pipeline by NeurOp, Inc, H2 2015 20
Brain Ischemia - Pipeline by Prolong Pharmaceuticals, H2 2015 21
Brain Ischemia - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 22
Brain Ischemia - Pipeline by Sylentis S.A., H2 2015 23
Brain Ischemia - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015 24
Brain Ischemia - Pipeline by Vect-Horus S.A.S , H2 2015 25
Assessment by Monotherapy Products, H2 2015 26
Number of Products by Stage and Target, H2 2015 28
Number of Products by Stage and Mechanism of Action, H2 2015 30
Number of Products by Stage and Route of Administration, H2 2015 32
Number of Products by Stage and Molecule Type, H2 2015 34
Brain Ischemia Therapeutics - Recent Pipeline Updates, H2 2015 60
Brain Ischemia - Dormant Projects, H2 2015 63
Brain Ischemia - Discontinued Products, H2 2015 64